Harmony Biosciences Holdings, Inc.: Business Overview, Financials & Competitive Analysis
Harmony Biosciences Holdings, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Rare disease pharma with proven blockbuster drug, expanding pipeline into multiple indications, and strong revenue growth trajectory. Strong WAKIX revenue growth trajectory with blockbuster status potential and pipeline expansion extending into the 2040s. Expanding addressable markets with a diversified pipeline and strong commercial execution position the company for.
What is Harmony Biosciences Holdings, Inc.'s industry? Harmony Biosciences Holdings, Inc. (harmonybiosciences.com) operates in Pharmaceuticals - Rare/Specialty Diseases. AskCyborg classifies Harmony Biosciences Holdings, Inc. under Pharmaceuticals - Rare/Specialty Diseases in its company registry.
Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. The company's flagship product, WAKIX (pitolisant), tr...
Cyborg Score thesis
Rare disease pharma with proven blockbuster drug, expanding pipeline into multiple indications, and strong revenue growth...
Read the full analyst-debate transcript →Get the Latest Harmony Biosciences Holdings, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHarmony Biosciences Holdings, Inc. Overview
Pro stress-test →Harmony Biosciences is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases. The company's flagship product, WAKIX (pitolisant), treats excessive daytime sleepiness in adult patients with narcolepsy and is on track for blockbuster status.
Strategic Profile
Pro stress-test →WAKIX generated $868 million in 2025 preliminary revenue with 2026 guidance of $1.0-$1.04 billion, demonstrating strong commercial execution. The company is expanding pitolisant across multiple neurological indications including Prader-Willi Syndrome in Phase 3 trials and Myotonic Dystrophy in Phase 2, while evaluating broader applications for H3 receptor-mediated disorders.
Competitive Landscape
Pro stress-test →Harmony is positioned in the rare neurological disease market with an expanding addressable market and diversified pipeline. Primary competition comes from other narcolepsy and rare neurological disease specialists, with Harmony's competitive advantage centered on WAKIX's novel H3 receptor mechanism and expanding multi-indication pipeline.
Industry Context
Harmony Biosciences Holdings, Inc. operates in Pharmaceuticals - Rare/Specialty Diseases.
Key facts
Founded: 2017 · Headquarters: Plymouth Meeting, Pennsylvania, United States · Employees: 293 · Revenue: $868M (2025 preliminary) · Market cap: $1.644B